Molnupiravir

Molnupiravir

Form: Oral capsule

Strength: 200 mg

Reference Brands: Lagevrio®(Us & EU)

Category: Anti Covid Medicines

Molnupiravir and Tocilizumab are high-demand COVID-19 treatments sourced globally through trusted PharmaB2B platforms. Molnupiravir (200 mg capsules, branded as Lagevrio, Molnatris, Molnunat) is used for mild to moderate cases, while Tocilizumab (IV and SC, branded as Actemra, Tocira) treats severe inflammation in hospitalized patients. Approved in the US, EU, and Asia, these products are available in bulk from verified manufacturers and exporters. PharmaB2B networks offer global distribution, regulatory-compliant sourcing, and competitive pricing. Connect with reliable suppliers today to ensure seamless supply chain solutions for hospitals, tenders, and distributors worldwide.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Baricitinib

Strength: 2 mg, 4 mg

Form: Tablet

Reference Brands: Olumiant®(EU & US- Emergency Use Authorization (EUA)

View Details Get Enquiry
Nirmatrelvir + Ritonavir

Strength: Nirmatrelvir(150 mg) + Ritonavir(100 mg)

Form: Tablet

Reference Brands: Paxlovid®(US & EU- For Emergency Use Authorization)

View Details Get Enquiry
Tocilizumab

Strength: IV: 80 mg/4 mL, 200 mg/10 mL, 400 mg/20 mL; SQ: 162 mg/0.9 mL (pen or syringe)

Form: IV injection, SQ Injection

Reference Brands: Actemra®(US); RoActemra®(EU)

View Details Get Enquiry
Favipiravir tablet

Strength: 200 mg, 400 mg, 600 mg

Form: Tablet

Reference Brands: Fabiflu, Favicovid, Covihalt, Avifavir, Avigan, Favira , Favilow(Globally, Not approved in USA & EU)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.